Oral Remdesivir Could Lower COVID Hospitalizations, Preclinical Study Says

An oral version of remdesivir is being developed by scientists at the University of California, San Diego (UCSD) to combat the SARS-CoV-2 virus early in its infection cycle.

Though still in preclinical trials, results suggest it could reduce disease severity and hospitalizations thanks to its longer half-life, greater efficacy and reduced toxicity when compared to remdesivir.